CDRH-2024-122027-Leakage Testing in Microfluidic Devices
Closed Solicitation Posted
Not the latest version. See the latest solicitation from .
- Solicitation number
- FDA-RFQ-CDRH-2024-122027
- Agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Place of performance
- Silver Spring, Maryland 20993, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The FDA is seeking to procure a leakage testing system that will be used for accurate detection of leaks in microfluidic devices under different operating conditions. This system will benefit FDA regulatory science research and significantly reduce the test method development time by removing the need for FDA to design, develop, build, test, and validate a custom solution. The solicitation lists key technical capabilities required for the system, including pressure decay testing, vacuum pressure ranges, leak detection sensitivity, and real-time data monitoring and recording. Proposals are due within 90 calendar days of award, and the FDA intends to award a firm-fixed price purchase order with a one-year warranty and technical support.
The solicitation is issued under full and open competition using Simplified Acquisition Procedures, with no set-aside designation. The place of performance is Silver Spring, MD 20993, USA. The solicitation does not name any potential incumbents or current contractors, and does not provide any information about award values or budget ranges.
Notice text
FDA needs a leakage testing system that will be used for accurate detection of leaks in microfluidic devices under different operating conditions (i.e., flow rates and pressures) to understand the performance of existing testing platforms for assessing emerging device technologies. This system will benefit FDA regulatory science research and significantly reduce the test method development time by removing the need for FDA to design, develop, build, test, and validate a custom solution. See attached.
Files
| File | Type | Posted |
|---|---|---|
| FDA-RFQ-CDRH-2024-122027 Leakage Testing in Microfluidic Devices S.docx | DOCX document |
Notice history
| Notice | Type | Posted |
|---|---|---|
| CDER-2024-123664 DM BNE- Agilent LCMSD iQ Mass Selective Detector-Brand Name or Equal. | Solicitation | |
| This notice | Solicitation | |
| ORA-2024-120488-Shredding Services For PHI-DO and Associated Resident Posts, for a base year (12 months) plus four (4) 12 (months) option years. | Solicitation | |
| CDRH-2023-118641 DIDSR2023-33705-Glass Pathology Slides of Cancer | Solicitation | |
| CDER-2023-118721 ss ChemiDOC MP Imaging System | Pre-Solicitation | |
| Advanced Product Characterization and Artificial Intelligence | Solicitation |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity